The transcription factors c-Myc and N-Myc-encoded by Myc and Mycn, respectively-regulate cellular growth 1 and are required for embryonic development 2, 3 . A third paralogue, Mycl1, is dispensable for normal embryonic development but its biological function has remained unclear 4 . To examine the in vivo function of Mycl1 in mice, we generated an inactivating Mycl1 gfp allele that also reports Mycl1 expression. We find that Mycl1 is selectively expressed in dendritic cells (DCs) of the immune system and controlled by IRF8, and that during DC development, Mycl1 expression is initiated in the common DC progenitor Mature DCs exhibit substantial proliferative activity 14, 15 . In a 4-h in vivo 5-bromo-29deoxyuridine (BrdU) pulse labelling, B cells, monocytes and neutrophils showed a low rate of ,1% BrdU uptake (Extended Data Fig. 1a) , whereas splenic conventional DC (cDC) subsets showed 4-8% BrdU uptake, consistent with previous studies 14, 15 . In agreement, 4-7% of cDCs were found to be in S/G2/M phase by DAPI (49,6-diamidino-2-phenylindole) staining and 17-34% were in active cell cycle by Ki-67 staining (Extended Data Fig. 1b) . Although splenic plasmacytoid DCs (pDCs) had little proliferative capacity, a significant fraction of pDCs in bone marrow were in S/G2/M phase by DAPI staining (Extended Data Fig. 1c) .
The transcription factors c-Myc and N-Myc-encoded by Myc and Mycn, respectively-regulate cellular growth 1 and are required for embryonic development 2, 3 . A third paralogue, Mycl1, is dispensable for normal embryonic development but its biological function has remained unclear 4 . To examine the in vivo function of Mycl1 in mice, we generated an inactivating Mycl1 gfp allele that also reports Mycl1 expression. We find that Mycl1 is selectively expressed in dendritic cells (DCs) of the immune system and controlled by IRF8, and that during DC development, Mycl1 expression is initiated in the common DC progenitor 5 concurrent with reduction in c-Myc expression. Mature DCs lack expression of c-Myc and N-Myc but maintain L-Myc expression even in the presence of inflammatory signals such as granulocyte-macrophage colony-stimulating factor. All DC subsets develop in Mycl1-deficient mice, but some subsets such as migratory CD103
1 conventional DCs in the lung and liver are greatly reduced at steady state. Importantly, loss of L-Myc by DCs causes a significant decrease in in vivo T-cell priming during infection by Listeria monocytogenes and vesicular stomatitis virus. The replacement of c-Myc by L-Myc in immature DCs may provide for Myc transcriptional activity in the setting of inflammation that is required for optimal T-cell priming 6 . c-Myc regulates cellular proliferation, metabolism and maintenance of progenitor populations 7, 8 and globally amplifies transcription by direct interactions with RNA polymerases I, II and III, accounting for its regulation of disparate and context-dependent target loci across cell types [9] [10] [11] . Forced expression of L-Myc exerts weaker effects than c-Myc for cell growth, apoptosis and transformation 12 but is more efficient in reprogramming fibroblasts towards induced pluripotent stem cells 13 . However, the in vivo function of L-Myc has not been established 4 . Mature DCs exhibit substantial proliferative activity 14, 15 . In a 4-h in vivo 5-bromo-29deoxyuridine (BrdU) pulse labelling, B cells, monocytes and neutrophils showed a low rate of ,1% BrdU uptake (Extended Data Fig. 1a ), whereas splenic conventional DC (cDC) subsets showed 4-8% BrdU uptake, consistent with previous studies 14, 15 . In agreement, 4-7% of cDCs were found to be in S/G2/M phase by DAPI (49,6-diamidino-2-phenylindole) staining and 17-34% were in active cell cycle by Ki-67 staining (Extended Data Fig. 1b) . Although splenic plasmacytoid DCs (pDCs) had little proliferative capacity, a significant fraction of pDCs in bone marrow were in S/G2/M phase by DAPI staining (Extended Data Fig. 1c ).
Myc and Mycn were highly expressed in various haematopoietic progenitor populations but were significantly reduced in mature DCs (Fig. 1a) . By contrast, Mycl1 was expressed by common DC precursors (CDPs), committed precursors to cDCs 5 (pre-cDCs) and by mature splenic DCs (Fig. 1a) , but not by other haematopoietic lineages 8 N-Myc during DC development. We compared c-Myc and L-Myc expression at a single-cell resolution using Myc gfp reporter mice 16 encoding a green fluorescent protein (GFP)-c-Myc amino-terminal fusion protein and a novel L-Myc allele, Mycl1 gfp , that substitutes gfp for the first coding exon (Extended Data Fig. 1f and Extended Data Fig. 2 ). c-Myc protein was highly expressed in Flt3
1 common myeloid progenitors (CMPs), was greatly reduced in CDPs and pre-cDCs (Fig. 1b, c) and was undetectable in mature splenic DCs (Fig. 1d, e) . By contrast, Mycl1 gfp was absent in CMPs, became detectible in CDPs and pre-cDCs (Fig. 1b, c) , and was highly expressed in mature splenic CD8a 1 cDCs, CD8a 2 cDCs, and pDCs, but not in neutrophils, monocytes, red pulp macrophages, natural killer (NK) cells and T and B cells (Fig. 1d-f) , consistent with Mycl1 messenger RNA expression (Extended Data Fig. 1d) .
DC subsets that developed in Mycl1 gfp/gfp (L-Myc-deficient) mice showed no compensatory induction of Myc expression (Extended Data Fig. 1g, h ). Mycl1 gfp expression was observed in DCs that developed from Flt3 ligand (Flt3L)-treated bone marrow cultures in vitro (Extended Data Fig. 3a, b) . Retroviral overexpression of c-Myc, but not L-Myc, into Flt3
1 CMPs reduced the proportion of mature cDCs and pDCs that developed in Flt3L cultures (Extended Data Fig. 3c, d ), suggesting that L-Myc may be non-redundant with c-Myc for DC development.
We Fig. 3f ) and was absent in macrophages in the peritoneum, kidney and liver (Extended Data Fig. 3g ). Mycl1 gfp -expressing DCs were abundant in the T-cell zones of spleen and lymph nodes, and less frequent within B-cell follicles and the splenic red pulp (Fig. 2c) . Sparse Mycl1 gfp -expressing DCs were present in the sub-capsular sinus of inguinal lymph nodes where Zbtb46 1 cDCs reside 17 (Fig. 2c ). In addition, Mycl1 gfp was expressed by CD4 2 B220 2 cells in small intestinal lamina propria, inside villi and within Peyer's patches (Fig. 2c) . Mycl1 gfp expression was not expressed in vascular endothelium, unlike Zbtb46 gfp (Extended Data  Fig. 4a, b) . Thus, Mycl gfp expression identifies DCs in both lymphoid and non-lymphoid peripheral tissues.
Mycl1 expression by CMPs has been reported to be IRF8-dependent 18 . In mice homozygous for the Irf8 R294C point mutation 19 that interrupts interactions between IRF8 and the transcription factor PU.1, Mycl1 gfp expression was absent in DC progenitors and substantially reduced in pDCs (Extended Data Fig. 5a, b) . Moreover, Mycl1 gfp was expressed in DCs differentiated from wild-type, but not Irf8
R294C
, Ly6C hi monocytes using interleukin (IL)-4 and granulocyte-macrophage colonystimulating factor (GM-CSF) 17,20 (Extended Data Fig. 5a , c). L-Myc protein was maintained in cDCs under various inflammatory conditions including treatment with interferon (IFN)-c and increased by treatment with GM-CSF ( Fig. 2d and Extended Data Fig. 5d ). Chromatin immunoprecipitation combined with massively parallel sequencing (ChIPseq) analysis identified several IRF8 binding regions across Mycl1 that did not require the transcription factor BATF3 (ref. 21) (Fig. 2e and Extended Data Fig. 5e-g ). Together, these results support a role for IRF8-PU.1 interactions in Mycl1 expression.
In lymphoid and peripheral tissues, absence of L-Myc decreased the total number and relative frequency of DCs, which competitive mixed bone marrow chimaeras suggested was due to a cell-intrinsic defect (Fig. 3a-c and Extended Data Fig. 6a-e) . The largest reduction was to Fig. 6f, g ). Thus, variations in the abundance of cell-extrinsic factors such as GM-CSF in the local tissue microenvironment result in different homeostatic requirements for DCs that are revealed by the loss of L-Myc. Analysis of gene expression microarrays from wild-type and L-Mycdeficient pDCs, CD8a 1 cDCs, and CD8a 2 cDCs identified a few presumed L-Myc target genes associated with cellular proliferation and apoptosis (Extended Data Fig. 7a, b) . In agreement, splenic CD8a 1 cDCs from L-Myc-deficient mice showed a 50% reduction in BrdU incorporation in vivo relative to wild-type mice (Fig. 3d) . Also, a tamoxifen-activated L-Myc fusion protein (L-Myc-ER T2 , in which ER T2 represents the mutant human oestrogen receptor) markedly and specifically increased proliferation of CD8a 1 cDCs (Fig. 3e) , suggesting that L-Myc can regulate DC proliferation. GM-CSF, a cytokine known to regulate DC homeostasis, increased CD8a 1 cDC cell size and expression of .500 genes, including many involved in regulation of apoptosis (Extended Data Fig. 7c-f) . Notably, the ability of GM-CSF to increase CD8a 1 cDC survival was impaired in the absence of L-Myc (Fig. 3f, g ). Genes that appear to be targets of L-Myc in CD8a 1 cDCs include eukaryotic translation initiation factor 1 (Eif1) and NADH dehydrogenase (ubiquinone) Fe-S protein 5 (Ndufs5), which could affect global protein translation and energy metabolism. Furthermore, of the 500 genes induced by GM-CSF treatment in wild-type DCs (Extended Data Fig. 7e ), 442 are reduced in expression in L-Myc-deficient CD8a 1 cDCs (Fig. 3h) , suggesting that the absence of L-Myc broadly limits inducible genes expressed in activated CD8a
1 cDCs. Finally, we assessed whether L-Myc expression was required for T-cell priming and other functions attributed to DCs 23, 24 . We measured antigen-specific CD8
1 and CD4 1 T-cell responses after infection with L. monocytogenes expressing soluble ovalbumin (LM-OVA). Loss of L-Myc significantly decreased the total number of IFN-c-producing OVA-specific CD8 1 and CD4 1 T cells (Fig. 4a, b and Extended Data Fig. 8a, b) . To demonstrate that these effects were not the result of a requirement for L-Myc in T cells, we adoptively transferred congenically marked L-Myc-sufficient OVA-specific OT-I CD8 1 T cells into wild-type and L-Myc-deficient mice. After infection with LM-OVA, OT-I CD8 1 T-cell expansion was considerably reduced in L-Mycdeficient mice as compared to wild-type mice (Fig. 4c, d ). L-Myc-deficient mice also showed impaired CD8 1 T-cell priming after infection with vesicular stomatitis virus expressing ovalbumin (VSV-OVA) (Extended Data Fig. 8c, d ). These priming defects were attributable to the action of L-Myc in CD8a 1 cDCs, as depletion of pDCs 25 or Notch2-dependent CD11b 1 cDCs 26 had no effect on CD8 1 T-cell priming after infection with LM-OVA (Extended Data Fig. 9a-c) . Further, the defect did not appear to involve processing and presentation of soluble antigen (Extended Data Fig. 10a, b) . Mixed chimaera analysis using Zbtb46 dtr/dtr mice 27 indicated that the priming defect is intrinsic to cDCs (Extended Data Fig. 9d-g ).
We recently showed that CD8a 1 cDCs are required for L. monocytogenes to establish infection in mice via the intravenous route, as Batf3 , which are the initial reservoir for bacterial expansion. Because L-Myc is most highly expressed in the CD8a 1 cDCs in spleen, we asked whether L-Myc deficiency might influence infection by L. monocytogenes. L-Myc-deficient mice were remarkably resistant to lethal infection by L. monocytogenes relative to wild-type mice (Fig. 4e) . This resistance was caused by significant reduction in the intracellular growth of bacteria within L-Myc-deficient CD8a 1 cDCs, and was not due to reduced bacterial capture or DC viability during the first 24 h of infection ( Fig. 4f and Extended Data Fig. 8e-h ). This reduced growth of L. monocytogenes was cell-intrinsic to CD8a 1 cDCs ( Fig. 4g and Extended Data Fig. 10c, d ) and was sufficient to prevent the subsequent spread of bacteria to other lineages ( Fig. 4h and Extended Data Fig. 10e ).
The functional relationship of L-Myc to other Myc factors has remained uncertain 4 . We show that L-Myc is selectively expressed in DCs, maintained gfp/gfp mice. The top 500 genes induced in wild-type cells following GM-CSF treatment are shown (green) (n 5 3 biological replicates, Welch's t-test). *P , 0.05, ***P , 0.001, NS, P . 0.05.
LETTER RESEARCH
during inflammation, and required by cDCs for optimal priming of T cells in bacterial and viral infection. As c-Myc is repressed by interferons 30 and inducible genes can depend on c-Myc, L-Myc may provide a means to support transcriptional responses required during T-cell priming by cDCs.
METHODS SUMMARY
Mice. Wild-type 129S6/SvEv mice were from Taconic. Wild-type C57BL/6 mice, 
Zbtb46
dtr/dtr and Irf8 R294C mice were described 16, 19, 26 . Irf8 R294C mice were backcrossed to C57BL/6 for 11 generations. Experiments used sex-and age-matched mice at 6-16 weeks of age. All pathogen infections were performed on mice of the 129S6/ SvEv genetic background unless indicated.
Myc, Mycn and Mycl1 expression in Fig. 1a was determined by microarrays for the long-term haematopoietic stem cell, Flt3
1 multipotent progenitor, CMP, granulocyte-macrophage progenitor, common lymphoid progenitor, CDP, bone marrow pre-cDC, splenic pDC, splenic CD8a 1 DC and splenic CD8a 2 DC. In Fig. 1b Fig. 2d , bone marrow cells were cultured for 9 days with Flt3L and treated with media, IL-4, IFN-c, GM-CSF or heat-killed L. monocytogenes strain EGD for 24 h.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. 1 T cells were measured from the indicated recipient mice after infection as described in c (error bars, 6 s.d., n 5 8, Student's t-test). Data in c, d are from 2 independent experiments. e, Survival of WT and KO mice after infection with L. monocytogenes (n 5 15, log-rank Mantel-Cox test). Data are from 3 independent experiments. f, L. monocytogenes was measured in purified CD8a
1 DCs after 2 h or 24 h of infection from e (error bars, 6 s.d., n 5 4-6 biological replicates, Student's t-test). g, Splenic CD8a
1 DCs from mice infected for 2 h were cultured in vitro in media with the indicated antibiotic for 12 h and viable intracellular bacteria quantified (error bars, 6 s.d., n 5 4, Student's t-test). Data in f, g are from 2 independent experiments. h, Viable intracellular bacteria were measured as in g from the indicated cells from WT and KO mice infected with L. monocytogenes for 60 h (error bars, 6 s.d., n 5 3, Student's t-test). **P , 0.001, NS, P . 0.05. 16, 19, 26 . Irf8 R294C mice were backcrossed to C57BL/6 for 11 generations. Experiments used sex-and age-matched mice at 6-16 weeks of age, without randomization or blinding. All pathogen infections were performed on mice of the 129S6/SvEv genetic background unless indicated.
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Myc, Mycn and Mycl1 expression in Fig. 1a was determined by microarrays for the long-term haematopoietic stem cell, Flt3 1 multipotent progenitor, CMP, granulocyte-macrophage progenitor, common lymphoid progenitor, CDP, bone marrow pre-cDC, splenic pDC, splenic CD8a 1 DC and splenic CD8a 2 DC. In Fig. 1b, lineage markers Fig. 2d , bone marrow cells were cultured for 9 days with Flt3L and treated with media, IL-4, IFN-c, GM-CSF or heat-killed L. monocytogenes strain EGD for 24 h. Generation of Mycl1 gfp mice. The Mycl1-gfp targeting construct was assembled using MultiSite Gateway Technology (Invitrogen). The pENTR-lox-GFP.Neo plasmid was constructed as published 17 . The 59 homology arm (1,584 bp) was amplified by PCR from EDJ22 ESC genomic DNA (129S6/SvEvTac background) using the following oligonucleotides, which contain attB4 and attB1 sites: 59-GGGGA CAACTTTGTATAGAAAAGTTGGTAGCCTGTTTATGATAACACA-39 and 59-GGGGACTGCTTTTTTGTACAAACTTGGTCCGCTCCCTGCGGGAGGG-39. The BP recombination reaction between the attB4-and attB1-flanked PCR product and pDONR P4-P1R (Invitrogen) resulted in the pENTR-Mycl1-5HA plasmid. The 39 homology arm (3,497 bp) was amplified by PCR from EDJ22 ESC genomic DNA using the following oligonucleotides, which contain attB2 and attB3 sites: 59-GGGGACAGCTTTCTTGTACAAAGTGGGTAAGGACCACCCGGGGGCT-39 and 59-GGGGACAACTTTGTATAATAAAGTTGTTAGTAGCCACTGAGGT ACG-39. The BP recombination reaction between the attB2-and attB3-flanked PCR product and pDONR P2R-P3 (Invitrogen) resulted in the pENTR-Mycl1-3HA plasmid. A LR recombination reaction was performed using pENTR-Mycl1-5HA, pENTR-lox-GFP.Neo, pENTR-Mycl1-3HA and pDEST DTA-MLS 31 to generate the final targeting construct. The SwaI linearized vector was electroporated into EDJ22 embryonic stem cells (129S6/SvEv background), and targeted clones were identified by Southern blot analysis. Probes were amplified from genomic DNA using the following primers: Mycl1_ProbeA_Forward (Fwd), TGCATG CCTGACAACAAGAC; Mycl1_ProbeA_Reverse (Rev), CCAATTCATCTAGAA TCCTACA; Mycl1_ProbeB_Fwd, ATGCTATTCTGAGGCCATTTG; and Mycl1_ ProbeB_Rev, GCCCCTTGATGTGTGCATAC. Blastocyst injections were performed and resulting male chimaeras were bred to female 129S6/SvEvTac mice. Genotyping was conducted by PCR to confirm germline transmission and to determine the genotype of progeny mice using primers Mycl1_59 UTR_Fwd (TGAACTCGCTCCCCTCAG), Mycl1_Exon1_Rev (GCACCAGCTCGAATTT CTTC) and Mycl1_GFP_Rev (AAGTCGTGCTGCTTCATGTG), which resulted in a wild-type band of 337 bp and a knockout band of 525 bp. For indicated experiments Mycl1 gfp mice were backcrossed to C57BL/6J for at least seven generations. The loxP-flanked neomycin resistance cassette was removed from the germline by crossing to B6.C-Tg(CMV-cre)1Cgn/J (The Jackson Laboratory) at F 4 and loss of the CMV-cre transgene in subsequent generations was confirmed by PCR. Generation of L-Myc-specific rabbit polyclonal antibody and immunoblot analysis. Murine full-length Mycl1 complementary DNA was PCR amplified from the splenic CD8a 1 cDC cDNA library. The resulting PCR product was ligated into the expression vector pET-28a(1) (Novagen) downstream of the His tag and the final plasmid was transformed into the Escherichia coli expression strain BL21-CodonPlus(DE3)-RIL (Stratagene). Recombinant L-Myc was expressed for 12 h at room temperature (22 uC) and then affinity purified on Ni-NTA His?Bind Resin (Novagen) according to manufacturer's instructions. Purified recombinant L-Myc was used to immunize New Zealand White Rabbits (Harlan Laboratories) according to a standard 112-day protocol. Finally, rabbit anti-mouse L-Myc sera were collected and L-Myc-specific antibody was affinity purified and tested by western blot analysis.
For immunoblot analysis, either whole-cell extracts were prepared with RIPA lysis buffer containing protease inhibitors, or nuclei were obtained after cellular lysis with buffer containing 0.2% Nonidet P40 as described 32 . Extracts were denatured in Laemmli sample buffer at 95 uC for 10 min, and 5 3 10 5 -1 3 10 6 cell equivalent of denatured extract was loaded per well of a 7.5% precast mini polyacrylamide gel (Bio-Rad). Proteins were then transferred onto a nitrocellulose membrane using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad) according to manufacturer's instructions. Blots were blocked with a solution containing 5% non-fat milk and 0.05% Tween-20 for 1 h at room temperature and then incubated with primary antibody overnight at 4 uC. After extensive washing, blots were incubated with a goat anti-rabbit IgG (H1L) conjugated to horseradish peroxidase (Jackson ImmunoResearch Laboratories) for 1 h at room temperature. Finally, blots were developed with ECL Western Blotting Substrate (Thermo Scientific) according to manufacturer's instructions.
c-Myc western blot analysis was performed similarly to the abovementioned protocol except a commercial rabbit anti-c-Myc antibody (Y69) was used (Abcam). Rabbit anti-GFP antibody (sc-8334, Santa Cruz Biotechnology) and rabbit anti-PLC-c2 (Santa Cruz Biotechnology) were used to determine equivalent loading across blots. BrdU incorporation and cell-cycle analysis. For in vivo BrdU-incorporation studies, mice of the C57BL/6 genetic background were injected intraperitoneally (i.p.) with 2 mg BrdU (Sigma) or intravenously (i.v.) with 1 mg BrdU in pyrogenfree saline. Splenocytes were collected after 4 h for i.p.-injected and after 1 h for i.v.-injected mice. Intracellular BrdU staining was performed with APC BrdU Flow Kit (BD Pharmingen) according to manufacturer's instructions following cell-surface staining. In vitro BrdU-incorporation studies to determine the frequency of cells in S phase of cell cycle were performed on sorted populations, which were then cultured for 24 h in 100 ng ml 21 Flt3L. To detect cells in S phase of cell cycle, 10 mM BrdU was added for the last 4 h of culture, after which cells were fixed, permeabilized and stained according to APC BrdU Flow Kit instructions. Analysis was performed on a BD FACSCanto II (BD Biosciences) and the event rate was maintained below 300 events per second on the lowest flow rate to ensure doublet exclusion. Total frequency of cells in S/G2/M phase of cell cycle was determined by DAPI staining of isolated populations as described previously 33 . Pathogen infections. L. monocytogenes expressing a secreted form of OVA (LM-OVA 34 ) was a gift from H. Shen (University of Pennsylvania School of Medicine). LM-OVA was stored as glycerol stocks at 280 uC and diluted into pyrogen-free saline for i.v. injection into mice. Mice were infected with 3 3 10 3 colony-forming units (c.f.u.) of LM-OVA and killed 7 days later for T-cell analysis unless otherwise indicated. Vesicular stomatitis virus encoding full-length ovalbumin (VSV-OVA) was a gift from L. Lefrancois (University of Connecticut Health Center) 35 . VSV-OVA stocks were stored in PBS at 280 uC and diluted into pyrogen-free PBS before injections into mice. Mice were infected i.v. with 5 3 10 6 plaque-forming units of virus and killed 7 days later for T-cell analysis unless otherwise indicated.
For lethal infectious challenge, the wild-type L. monocytogenes strain EGD (LM-EGD) was used in this study 28 . Mice were infected intravenously with 10 5 c.f.u. wild-type L. monocytogenes and followed daily for survival by an observer who had been blinded to the genotypes of each cage of mice. Listeria was stored as glycerol stocks at 280 uC and diluted into pyrogen-free saline for i.v. injection into mice. A dose of 10 5 c.f.u. diluted from concentrated frozen stocks was determined to be 80-90% lethal for 8-week-old wild-type male mice on the C57BL/6 genetic background. Mycl1 gfp/gfp mice on the 129S6/SvEv genetic background were backcrossed for ten generations with mice on the C57BL/6 genetic background to establish Mycl1 gfp/gfp mice on C57BL/6 background for lethal Listeria challenge. Purification of bacteria-infected splenocytes. Wild-type and Mycl1 gfp/gfp mice on the C57BL/6 genetic background were infected i.v. with LM-EGD or LM-OVA and splenocytes were collected at 2 h (5 3 10 5 c.f.u. LM-EGD), 24 h (1 3 10 5 c.f.u. LM-EGD or LM-OVA) or 60 h (8 3 10 4 c.f.u. LM-EGD) as described 29, 36 . In brief, single-cell suspensions were prepared with gentamicin-containing media (5 mg ml 21 ) to kill extracellular bacteria. DCs were enriched with CD11c 1 MACS microbeads (Miltenyi) according to manufacturer's instructions and purified by cell sorting on BD FACSAria II (BD Biosciences). Live/dead discrimination was performed with propidium iodide (Sigma). After washing in PBS, sorted cells were lysed with 13 PBS supplemented with 0.05% Triton X-100 and plated on Brain Heart Infusion (BHI) plates to quantify bacteria. For short-term ex vivo culture, sorted CD8a 1 DCs were washed with 13 PBS, re-suspended in media containing either gentamicin (5 mg ml
21
) or penicillin/streptomycin (100 U ml 21 and 100 mg ml
, respectively), and 5 3 10 4 DCs were cultured in 96-well flat bottom plates in final volume of 200 ml media. Cells were collected, washed twice with 13 PBS and either lysed for bacteria quantification or stained for viability (see below). For ex vivo T-cell stimulation, 5 3 10 3 DCs were sorted and cultured with 3 3 10 4 purified CFSElabelled OT-I CD8
1 T cells in a 96-well round bottom plate. Cells were collected after 60 h and T cells quantified as described 37 .
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In vitro T-cell re-stimulation after LM-OVA or VSV-OVA infection. Seven days after infection, spleens were mechanically disrupted, red blood cells were lysed with ammonium chloride-potassium bicarbonate (ACK) lysis buffer, and single cell suspensions were counted on a Vi-CELL (Beckman Coulter). cells were analysed by flow cytometry to confirm 1:1 chimaerism before transplantation. 5-10 3 10 6 total bone marrow cells were transplanted by retro-orbital injection into wild-type B6.SJL recipients that had been conditioned with two doses of 525 rads of whole-body irradiation-with an interval of 4 h between the doses-on the day of transplantation, and mice were infected 8-10 weeks later. The mixed bone marrow chimaeras in Fig. 3 were generated from CD45. 1 in peripheral blood neutrophils). Chromatin immunoprecipitation (ChIP). ChIP was carried out as described previously 38 . In summary, 30 3 10 6 DCs from a 10-day Flt3L culture of bone marrow from wild-type mice, Irf8 2/2 mice and Batf3 2/2 mice were collected, washed twice with ice-cold 13 PBS and re-suspended in 13 PBS. Cells were crosslinked for 13 min at room temperature by the addition of one-tenth of the volume of 11% formaldehyde solution. Following the final wash, supernatant was discarded and cell pellets were flash frozen in liquid nitrogen for storage at 280 uC. Thawed cell pellets were lysed with lysis buffer 1, washed with lysis buffer 2, and resuspended in lysis buffer 3 for sonication. Chromatin was sonicated for 36 cycles of 15 s on and 20 s off per cycle with a Misonix Sonicator XL2020 outfitted with a Microtip and operated at a power setting between 2-3. Sheared DNA was run on a 2% agarose gel stained with ethidium bromide and imaged to determine the average size, which was between 200 and 300 bp. Sonicated lysates were incubated overnight at 4 uC with magnetic beads bound to anti-IRF8 antibody to enrich for DNA fragments. Magnetic beads were prepared by blocking 50 ml of Protein G Dynabeads (Invitrogen) with 0.5% BSA (w/v) in PBS, followed by an overnight incubation with 5 mg of goat anti-IRF8 (C-19, Santa Cruz) at 4 uC. Beads containing DNA fragments were washed with RIPA buffer and Tris-EDTA 1 50 mM NaCl. Bound complexes were eluted in elution buffer at 65 uC for 15 min with vortexing every 3 min. Crosslinks were reversed overnight at 65 uC. RNA and protein were digested with RNase A and Proteinase K, respectively, and DNA was purified with phenol:chloroform extraction followed by ethanol precipitation.
ChIP DNA was subjected to end repair, addition of an 'A' base to 39 ends, and ligation of sequencing adapters. The fragments were size selected to 200-600 bp and underwent amplification for 15 cycles. The resulting libraries were sequenced using the Illumina HiSeq 2500 as single reads extending 50 bases. Data were demultiplexed and aligned to the reference genome using Novoalign. ChIP-seq data processing and analysis. ChIP-seq data sets were aligned using Novoalign (Novocraft Technologies) to build NCBI37/mm9 of the mouse genome. Alignments were carried out using the following parameters '-o SAM -r random -l 30 -e 100 -a AGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG -H'. Aligned and raw data can be found online under the Gene Expression Omnibus (GEO) series accession GSE53311. We used model-based analysis of ChIP-seq (MACS v1.4.2) 39 peak finding algorithm to identify genomic regions enriched for IRF8 binding. A maximum of 1 duplicate tag and a P value cutoff of 1 3 10 29 were used for all data sets. Background estimates were made using ChIP-seq on Irf8 2/2 DCs as the control. Annotation (mm9) of the obtained peaks was performed using 'annotatePeaks.pl' program of the Homer software package 40 . Peaks were further analysed for de novo motif discovery by using the 'findMotifsGenome.pl' program of the Homer software package using default parameters except for '-size 50 -S 10'. qRT-PCR. Wild-type myeloid and lymphoid cells from spleens of C57BL/6 mice were sorted to greater than 95% purity on a BD FACSAria II (BD Biosciences). DNase-treated total RNA was prepared with RNeasy Micro Kit (Qiagen) and firststrand cDNA synthesis was performed with SuperScript III Reverse Transcriptase (Invitrogen) using Oligo(dT)20 Primer (Invitrogen). Relative quantification of gene expression was performed on a StepOnePlus Real-Time PCR System (Applied Biosystems) according to the relative standard curve method and using HotStart-IT SYBR Green qPCR Master Mix (Affymetrix/USB). PCR conditions were 10 min at 95 uC, followed by 40 two-step cycles consisting of 15 
1
) from wild-type and Mycl1 gfp/gfp mice on the 129S6/SvEv genetic background were sorted to greater than 95% purity on a BD FACSAria II (BD Biosciences).
Splenic CD8a
1 DCs (gated as CD11c
2 ) and CD8a
2 DCs (gated CD11c
2 ) from wild-type and Mycl1 gfp/gfp mice on the C57BL/6 genetic background were similarly sorted. For short-term ex vivo culture and stimulation, the indicated splenic DCs were purified by cell sorting and plated in flat-bottom tissue-culture treated plates at a density of 10 5 per 200 ml; CD8a 1 DCs were stimulated with 10 ng ml 21 GM-CSF (PeproTech); after 24 h, cells were collected by pipetting repeatedly and washed twice with 13 PBS. DNase-treated total RNA was isolated from cells using the Ambion RNAqueous-Micro Kit. For Mouse Gene 1.0 ST Arrays, RNA was amplified with the Ovation Pico WTA System (NuGEN), and then fragmentation and labelling was performed with the Encore Biotin Module (NuGEN). Backgroundcorrected expression values were normalized using Robust Multi-array Average (RMA) quantile normalization and expression values were modelled using ArrayStar software (DNASTAR). All original microarray data have been deposited in GEO series accession GSE53312. Myc family expression values were determined from the following published microarray data sets: haematopoietic progenitors (GSE14833, GSE20244), DC progenitors (GSE37030) and mature DC subsets (GSE9810); DCspecific expression of Mycl1was determined using DC progenitors, mature DC subsets, and a murine tissue panel (GSE10246) excluding DCs. GSEA 41 (Broad Institute) was used to compare lung and lymph node DC gene expression profiles. We used the 'KEGG_Cell_Cycle' list under C2 (curated gene sets). Enrichment was assessed using gene set permutations (31,000) and log 2 ratio of classes used for ranked list metric. Lung and mediastinal lymph node CD103 1 DC microarrays were obtained from the Immunological Genome Project data set (GSE15907). Gene Ontology (GO) term enrichment was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID, http://david.niaid. nih.gov) 42 to determine whether particular gene ontology terms occur more frequently than expected by chance in a given set of genes. Probe-set identifiers for genes enriched at least twofold in wild-type CD8a
1 DCs treated with GM-CSF relative to wild-type CD8a
1 DCs treated with media were exported from ArrayStar and uploaded into DAVID for subsequent analysis. We used the category GOTERM_BP_FAT along with Functional Annotation Clustering. Ex vivo stimulation of DCs and viability assessment. Splenic CD8a 1 DCs were purified by cell sorting from wild-type and Mycl1 gfp/gfp mice on the C57BL/6 genetic background and washed with 13 PBS before culture. Cells were incubated in 96-well sterile plates at a density of 1-2.5 3 10 5 cells per ml. CD8a 1 DCs were treated with 10 ng ml 21 GM-CSF (PeproTech). After the indicated treatment duration, cells were collected by pipetting gently and washed twice with 13 PBS. Cell viability was determined by staining with Annexin V (BD Biosciences) and 7-AAD according to manufacturer's instructions. Immunofluorescence microscopy. Spleens and lymph nodes were fixed in 2% methanol-free paraformaldehyde (Electron Microscopy Sciences) for 12 h followed by incubation in 30% sucrose/H 2 O overnight, embedded in OCT compound, and cryo-sectioned at 8 mm. Staining of sections, image acquisition and processing were performed as published 17 . In brief, sections were blocked/stained in CAS Block (Invitrogen) supplemented with 0.2% Triton X-100 and mounted with ProLong Gold Antifade reagent containing DAPI (Invitrogen). Monochrome images were acquired with either 310 or 320 objective and exported into ImageJ software for subsequent colour balancing and overlaying.
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DC and macrophage preparation. DCs from lymphoid organs and non-lymphoid organs were collected and prepared as described 43 . In brief, spleens and lymph nodes were minced and digested in 5 ml Iscove's Modified Dulbecco's Media 1 10% FCS (complete IMDM) with 250 mg ml 21 collagenase B (Roche) and 30 U ml
21
DNase I (Sigma-Aldrich) for 30 min at 37 uC with stirring. Cells were passed through a 70-mm strainer before red blood cell lysis. Cells were then counted on a Vi-CELL analyser, and 5-10 3 10 6 cells were used per antibody staining reaction. Lung, liver and kidney cell suspensions were prepared after perfusion with 10 ml Dulbecco's PBS. Dissected and minced tissues were digested in 5 ml complete IMDM with 4 mg ml 21 collagenase D (Roche) for 1 h at 37 uC with stirring. Digested tissues were filtered and red blood cells lysed as above. Cells from the peritoneal cavity were collected by flushing with 10 ml PBS 1 5% FCS and 2 mM EDTA. Epidermal and dermal cell suspensions were prepared as described previously 44 . Microglia were isolated as described previously 33 . Last, small intestine lamina propria cells were isolated as described previously 45 .
In vitro bone marrow-derived dendritic cells. Femurs and tibias were manually flushed to collect bone marrow cells, and then red blood cells were lysed in ACK lysis buffer. To obtain Flt3L-derived pDC and cDC equivalents, bone marrow cells were cultured in complete IMDM at a density of 2 3 10 6 cells per ml containing 150 ng ml 21 murine Flt3L (PeproTech) for 9 or 10 days. Alternatively, GM-CSF DCs were obtained by culturing bone marrow cells in complete IMDM at a density of 6 3 10 5 cells per ml containing 20 ng ml 21 murine GM-CSF (Peprotech) for 8 days. Non-adherent cells were collected for FACS analysis or sorting. Sorted progenitors were cultured at a density of 5 3 10 4 cells per ml for either 24 h or 4 days in 100 ng ml 21 Flt3L. Plasmids and retroviral infection of DCs. cDNA for Mycl1 was generated by PCR from cDNA of CD8a 1 DCs. We used the previously described method for generating a functional Myc-ER fusion protein 46 , which placed a segment of the oestrogen receptor at the carboxy terminus of the Myc protein. Specifically, the cDNA for ER T2 was obtained by PCR from the p-Cre-ER T2 vector (a gift from T. Egawa, Washington University School of Medicine) and cloned into the retroviral plasmid MSCV-IRES-GFP, creating the construct ER T2 -MSCV-IRES-GFP. After removing the stop codon, Mycl1 cDNA was cloned upstream of the ER T2 sequence derived from Cre-ER T2 (refs 47, 48) , creating the plasmid L-Myc-ER T2 -MSCV-IRES-GFP. Retroviral plasmids were transfected into Phoenix-E packaging cells as described previously 49 , and Flt3L cultures were infected as described previously 21 except infections were performed on day 4. cDNA for murine Irf8 and Myc were generated by PCR from cDNA of splenocytes of C57BL/6 mice, sequenced to confirm identity, and cloned into the MSCV-IRES-GFP retroviral plasmid.
For transduction of macrophage-DC progenitors (MDPs), we isolated MDPs from the bone marrow of 6-week-old C57BL/6 mice and cultured them for 12 h in Flt3L before transduction. Transduced MDPs were allowed to differentiate for an additional 5 days before analysis. Antibodies and flow cytometry. Staining was performed at 4 uC in the presence of Fc block (clone 2.4G2, BD Biosciences) in FACS buffer (PBS, 0.5% BSA, 2 mM EDTA). The following antibodies were purchased from BD Biosciences: V450 and PerCP-Cy5.5 anti-NK1.1 (PK136), V450 anti-Ly6C/G (RB6-8C5), V450 anti-Ly6C (AL21), V500 anti-B220 (RA3-6B2), PE and PE-Cy7 anti-CD8a (53-6.7), PE-Cy7 and APC anti-CD4 (RM4-5), PE-Cy7 anti-CD24 (M1/69), PerCP-Cy5.5 anti-Ly6G (1A8), FITC and APC anti-CD172a/Sirpa (P84). The following antibodies were purchased from eBioscience: PE anti-NKp46 (29A1.4), PerCP-Cy5.5 and Alexa Fluor700 anti-CD11b (M1/70), APCeFluor780 anti-CD11c (N418), PE anti-CD103 (2E7), APC anti-CD317/BST2 (eBio927), eFluor450 anti-MHC-II (I-A/I-E) (M5/ 114.15.2), FITC and APC anti-CD45.2 (104), PE-Cy7 and PerCP-Cy5.5 anti-CD45.1 (A20), PerCP-Cy5.5 anti-CD16/32 (93), PE-Cy7 anti-cKit (2B8), eFluor450 anti-CD105 (MJ7/18), eFluor450 and Biotin anti-Ter119, PE anti-CD135 (A2F10), Alexa Fluor 700 and PerCP-Cy5.5 anti-Sca1 (D7), FITC, APC and PerCP-eFluor710 anti-SiglecH (eBio440C), Biotin and APC anti-CD115 (AFS98). The following antibodies were purchased from Miltenyi: PE anti-CD205/Dec205 (NLDC-145) and APC anti-CD205/Dec205 (NLDC-145). The following antibodies were purchased from Invitrogen: APC anti-F4/80 (BM8), PE anti-B220 (RA3-6B2), FITC and APC anti-CD8a (5H10). The following antibodies were purchased from Biolegend: PE and APC anti-SiglecH (551), Biotin anti-Ly6G (1A8), Biotin anti-MHC-II (M5/114.15.2). Statistical analysis. Analysis of all data was done with Prism 6 (GraphPad Software). P values were calculated with Student's t-test, Mann-Whitney U-test, ANOVA with appropriate post-hoc test, or log-rank Mantel-Cox test as specified in figure legends. P values less than 0.05 were considered significant.
Extended Data Figure 1 | Mycl1 expression 
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